More articles from Letters to the editor

  • Prostate cancer screening

    Kevin Kurator, BS, BA and Ian Jenkins, MD
    • Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260;
    • DOI: https://doi.org/10.3949/ccjm.88c.05002

    • Screening should be advised only if benefits clearly outweigh the risks

  • In Reply: Prostate cancer screening

    Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
    • Cleveland Clinic Journal of Medicine May 2021, 88 (5) 261;
    • DOI: https://doi.org/10.3949/ccjm.88c.05003

    • Detection does not lead to overtreatment.

  • Prostate cancer screening

    Sherry Zhang, MD and Ian Jenkins, MD
    • Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260;
    • DOI: https://doi.org/10.3949/ccjm.88c.05001

    • The costs of PSA testing—both financial and to the patient’s well-being—are not worth it.

  • In Reply: Prostate cancer screening

    Timothy Gilligan, MD
    • Cleveland Clinic Journal of Medicine May 2021, 88 (5) 262;
    • DOI: https://doi.org/10.3949/ccjm.88c.05004

    • The debate about screening remains fraught, and passions run high on both sides.

  • Assessing stable coronary artery disease

    Taher Modarressi, MD
    • Cleveland Clinic Journal of Medicine December 2020, 87 (12) 713;
    • DOI: https://doi.org/10.3949/ccjm.87c.12003

    • Differences between the coronary calcium score and CT coronary angiography

  • In Reply: Assessing stable coronaryartery disease

    Vinayak Nagaraja, MD and A. Michael Lincoff, MD
    • Cleveland Clinic Journal of Medicine December 2020, 87 (12) 714;
    • DOI: https://doi.org/10.3949/ccjm.87c.12004

    • CT angiography is the appropriate test to exclude left main disease.

  • Dexamethasone or hydrocortisone in COVID-19?

    Chia Siang Kow and Syed Shahzad Hasan
    • Cleveland Clinic Journal of Medicine December 2020, 87 (12) 715;
    • DOI: https://doi.org/10.3949/ccjm.87c.12005

    • Dexamethasone should be favored over hydrocortisone.

  • In Reply: COVID-19 coagulopathy

    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    • Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712;
    • DOI: https://doi.org/10.3949/cjm.87c.12002

    • An attempt to balance the potential risks and benefits of intensified prophylaxis.

  • COVID-19 coagulopathy

    Anup Katyal, MD
    • Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712;
    • DOI: https://doi.org/10.3949/ccjm.87c.12001

    • Skepticism of high-intensity prophylaxis for patients with D-dimer ≥ 3.0 µg/mL.

  • The R in PRES

    Amado Jiménez-Ruiz, MD, Miguel García-Grimshaw, MD, Juan Andrés Calderón-Martínez, MD and Isael Reyes-Melo, MD
    • Cleveland Clinic Journal of Medicine October 2020, 87 (10) 584-585;
    • DOI: https://doi.org/10.3949/ccjm.87c.10001

    • Posterior reversible encephalopathy syndrome lacks universal diagnostic criteria.

Previous
Next